- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Not listed
- Lead sponsor
- Florida International University
- Other
- Eligibility
- 16 Years to 30 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Amherst, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 807
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- ADHD
- Interventions
- Classroom Behavior Support (CBS) Condition, Standard Problem Solving Consultation
- Behavioral
- Lead sponsor
- Ohio University
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Athens, Ohio
- Conditions
- Autism, Attention Deficit Hyperactivity Disorder
- Interventions
- Methylphenidate Transdermal System
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- Care Manager CM), ADHD Portal
- Behavioral · Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- SPN-810
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 491 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder With Hyperactivity, Mental Disorders Diagnosed in Childhood, Attention Deficit and Disruptive Behavior Disorders
- Interventions
- Methylphenidate ER, Cyproheptadine
- Drug
- Lead sponsor
- Douglas Sears
- Individual
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Van Nuys, California
- Conditions
- Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Not listed
- Enrollment
- 12,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2030
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 18 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Active Neurofeedback, Sham neurofeedback
- Device
- Lead sponsor
- L. Eugene Arnold
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Autism Disorder, Language Development Disorders, ADHD, Typical Development, Rural Health, Children, Neuroimaging, Eye Tracking, EEG, fNIRS
- Interventions
- Speech-Gesture combinations
- Behavioral
- Lead sponsor
- Montana State University
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Bozeman, Montana
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Guanfacine, Methylphenidate (MPH)
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 7 Years to 14 Years
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- SHP465
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Orlando, Florida • Evansville, Indiana + 5 more
- Conditions
- Attention-deficit/Hyperactivity Disorder
- Interventions
- Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 81
- States / cities
- Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 68 more
- Conditions
- Traumatic Brain Injury (TBI), Attention Deficit Hyperactivity Disorder (ADHD), Head Injury, Brain Concussion, Head Injuries, Closed
- Interventions
- AIM
- Behavioral
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 10 Years to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- ADHD
- Interventions
- galantamine HBr
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 58 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
- Interventions
- NRP104
- Drug
- Lead sponsor
- New River Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine Hydrochloride
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- ADHD
- Interventions
- Mixed amphetamine salts (ADDERALL XR), Atomoxetine hydrochloride
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- OPDC-34712, Placebo, Stimulant Therapy
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 740 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 35
- States / cities
- Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more
- Conditions
- Neurocognitive Impairment, Acute Lymphoblastic Leukemia
- Interventions
- Neurocognitive and behavioral evaluation
- Other
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 8 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- NFC-1 100 mg, NFC-1 200 mg, NFC-1 400 mg, NFC-1 800 mg
- Drug
- Lead sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 3
- States / cities
- Maitland, Florida • Miami, Florida • Las Vegas, Nevada
- Conditions
- Cerebrovascular Accident, Transient Ischemic Attack, ADHD
- Interventions
- atomoxetine, Stimulants, No intervention (general population)
- Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Adult Attention Deficit Hyperactivity Disorder
- Interventions
- Serdexmethylphenidate/dexmethylphenidate
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Adult Attention Deficit Hyperactivity Disorder
- Interventions
- Dasotraline, Placebo
- Drug · Other
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 636 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 48 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- NS2359, Placebo
- Drug
- Lead sponsor
- NeuroSearch A/S
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts